Compassionate Use Study of Tenalisib (RP6530)

Summary

Tenalisib has been evaluated as an investigational new drug in number of early clinical studies in patients with relapsed/refractory hematological malignancies and demonstrated acceptable safety and promising efficacy in these patients. Since these advanced relapsed/refractory patients have limited therapeutic options, it is reasonable to continue Tenalisib in responding patients post completion of their participation in previous clinical studies.

Timeline

Start

2018-11-28

Primary completion

2023-03-25

Completion

2023-03-25

Drugs

Indications